A Phase I Open-Label, Single-Arm, Dose-Escalation Clinical and Pharmacology Study of CCI-001 as Monotherapy and in Combination With Standard Chemotherapy in Patients With Recurrent and/or Metastatic Solid Tumours

NCT04823897 · clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
70
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

PharmaMatrix Holdings Ltd

Collaborators